Reuters
22 Jun 2026, 20:43 UTC · 3h ago
Pfizer's experimental drug misses main goal of lung cancer trial
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Reuters
22 Jun 2026, 20:43 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
1 claim · each scored for market impact
Pfizer's lung cancer drug failed to meet the primary endpoint of its late-stage clinical trial. — Failure in late-stage trials removes a potential revenue stream and negatively impacts investor confidence in the company's pipeline.
-0.60Which stocks this story touches
The company's lung cancer drug missed the primary goal of a late-stage clinical trial.
Continue reading
6 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
10h ago
